CNTA

Centessa Pharmaceuticals

CNTA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)99%

Price to earnings ratio-27.7

Market capitalization6.3B

Earnings per share-1.78

Dividend yield (TTM)—

Revenue (annual)15M

Net income (annual)-197.5M

Centessa Pharmaceuticals plc American Depositary Receipt

Healthcare
Biotechnology

Centessa Pharmaceuticals plc American Depositary Receipt represents shares in Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company headquartered in Altrincham, United Kingdom, and founded in 2020. The company discovers and develops innovative medicines to address high unmet needs in various therapeutic areas, including oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Its pipeline features a diverse portfolio of uncorrelated programs ranging from preclinical to Phase 3 stages, such as SerpinPC targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, MGX292 for Pulmonary Arterial Hypertension, and additional undisclosed assets for solid tumors. ORX142, a novel Orexin Receptor 2 agonist, is advancing in clinical development with recent FDA clearance for Phase 1 studies. Centessa Pharmaceuticals plc focuses on delivering transformational therapies through its integrated platform, emphasizing orexin receptor agonists and other novel mechanisms to treat complex diseases like sleep disorders and beyond.

Website

Location

1 Ashley Road

Altrincham, WA14 2DT

United Kingdom

Centessa Pharmaceuticals

CNTA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)99%

Price to earnings ratio-27.7

Market capitalization6.3B

Earnings per share-1.78

Dividend yield (TTM)—

Revenue (annual)15M

Net income (annual)-197.5M

Social

What share of all stock conversation is about CNTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Apr 1

Centessa Pharmaceuticals plc (CNTA) has been acquired by Eli Lilly (LLY) in a deal worth up to $7.8B, with CNTA's pipeline of OX2R agonists being a key focus.
The acquisition is seen as a strategic move by LLY to diversify its portfolio beyond its GLP-1 dominance and expand into the sleep-wake disorder market.
CNTA's stock surged 44% on the news, while LLY gained around 4%, indicating strong market approval of the deal.

Generated by AI

Sentiment

Of the messages about CNTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	98.57%	99.57% +28.14	93.77% -0.92
Bearish	100%	1.43%	0.43% -28.14	6.23% +0.92

Mar 31

Eli Lilly is acquiring Centessa Pharmaceuticals for up to $47 per share, a 70% premium, to advance treatments for sleep-wake disorders.
The acquisition expands Eli Lilly's neuroscience pipeline and is a strategic move to secure the next blockbuster category in the industry.
The deal's structure, with a cash payment and up to $9 CVR, provides a clear path to potential payouts, unlike some other CVR deals in the biotech space.

Generated by AI

Topics

Of the messages about CNTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	6.54%
Announcements	100%	100%	99.57%	85.51%
Controversies	0%	0%	0%	0.64%
Earnings	0%	0%	0%	0.06%
Macro	0%	0%	0.43%	2.18%
Technical Analysis	0%	0%	0%	5.06%

Analysts· Jun 22

Centessa Pharmaceuticals plc has received Buy ratings and price targets from analysts, including $35 from Jefferies, $37 from Morgan Stanley, and $42 from Goldman Sachs.
Analysts have initiated coverage on Centessa Pharmaceuticals, with Goldman Sachs, Jefferies, and Morgan Stanley assigning Buy, Buy, and Overweight ratings, respectively.
Price targets for Centessa Pharmaceuticals have been set by analysts, with Jefferies at $35, Morgan Stanley at $37, and Goldman Sachs at $42.

Announcements· Mar 31

Eli Lilly is acquiring Centessa Pharmaceuticals in a $6.3B deal, offering $38 per share plus up to $9 in contingent value rights.
The acquisition expands Lilly's neuroscience pipeline with Centessa's OX2R agonist program, targeting narcolepsy and other sleep-wake disorders.
The deal is subject to approval and is expected to close in Q3 2026, with Centessa's shares rallying 43% on the news.

Generated by AI

Community

Of the messages about CNTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	94.76%	92.18%	39.31%
Newcomers	100%	5.24%	7.82%	60.69%

Regulars· Nov 12

The company has priced a $250 million public offering of American Depositary Shares at $21.50 per share, with underwriters holding an option for 1.74 million more shares.
The efficacy of Centessa Pharmaceuticals' NT2 dose is uncertain, with the company having only 5 patients on the highlighted dose, making it difficult to draw conclusions.
Morgan Stanley has maintained an Overweight rating on Centessa Pharmaceuticals, with a $27 target price, after the company's ORX750 outperformed Alkermes' drug.

Newcomers· Apr 1

New investors are interested in Centessa Pharmaceuticals' ($CNTA) recent 44% price surge, with some noting it's created a new 1-year high.
The $LLY / $CNTA merger announcement is sparking interest in the company, with some focusing on its potential to enter the sleep disorder market and its development of orexin-targeting drugs.
The high volume and RSI overbought signal on $CNTA's chart are causing some to take notice, with a few speculating on the company's potential for further growth.

Generated by AI

Also Discussed

Investors talking about CNTA also mention

#	Name	Attention
1	APLS - Apellis Pharmaceuticals, Inc.	——
2	EQRX - EQRx, Inc.	——
3	Kura Oncology, Inc.KURA	0%+0
4	Maze Therapeutics, Inc.MAZE	0%0
5	MoonLake Immunotherapeutics Class A Ordinary SharesMLTX	0.01%+0
6	Alkermes plcALKS	0%0
7	Oric Pharmaceuticals, Inc.ORIC	0%0
8	PSTX - Poseida Therapeutics, Inc.	——
9	Cytokinetics, IncorporatedCYTK	0.01%+0
10	VIGL - Vigil Neuroscience, Inc.	——

Centessa Pharmaceuticals plc American Depositary Receipt

Healthcare
Biotechnology

Website

Location

1 Ashley Road

Altrincham, WA14 2DT

United Kingdom

Social

What share of all stock conversation is about CNTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Apr 1

Centessa Pharmaceuticals plc (CNTA) has been acquired by Eli Lilly (LLY) in a deal worth up to $7.8B, with CNTA's pipeline of OX2R agonists being a key focus.
The acquisition is seen as a strategic move by LLY to diversify its portfolio beyond its GLP-1 dominance and expand into the sleep-wake disorder market.
CNTA's stock surged 44% on the news, while LLY gained around 4%, indicating strong market approval of the deal.

Generated by AI

Sentiment

Of the messages about CNTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	98.57%	99.57% +28.14	93.77% -0.92
Bearish	100%	1.43%	0.43% -28.14	6.23% +0.92

Mar 31

Eli Lilly is acquiring Centessa Pharmaceuticals for up to $47 per share, a 70% premium, to advance treatments for sleep-wake disorders.
The acquisition expands Eli Lilly's neuroscience pipeline and is a strategic move to secure the next blockbuster category in the industry.
The deal's structure, with a cash payment and up to $9 CVR, provides a clear path to potential payouts, unlike some other CVR deals in the biotech space.

Generated by AI

Topics

Of the messages about CNTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	6.54%
Announcements	100%	100%	99.57%	85.51%
Controversies	0%	0%	0%	0.64%
Earnings	0%	0%	0%	0.06%
Macro	0%	0%	0.43%	2.18%
Technical Analysis	0%	0%	0%	5.06%

Analysts· Jun 22

Centessa Pharmaceuticals plc has received Buy ratings and price targets from analysts, including $35 from Jefferies, $37 from Morgan Stanley, and $42 from Goldman Sachs.
Analysts have initiated coverage on Centessa Pharmaceuticals, with Goldman Sachs, Jefferies, and Morgan Stanley assigning Buy, Buy, and Overweight ratings, respectively.
Price targets for Centessa Pharmaceuticals have been set by analysts, with Jefferies at $35, Morgan Stanley at $37, and Goldman Sachs at $42.

Announcements· Mar 31

Eli Lilly is acquiring Centessa Pharmaceuticals in a $6.3B deal, offering $38 per share plus up to $9 in contingent value rights.
The acquisition expands Lilly's neuroscience pipeline with Centessa's OX2R agonist program, targeting narcolepsy and other sleep-wake disorders.
The deal is subject to approval and is expected to close in Q3 2026, with Centessa's shares rallying 43% on the news.

Generated by AI

Community

Of the messages about CNTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	94.76%	92.18%	39.31%
Newcomers	100%	5.24%	7.82%	60.69%

Regulars· Nov 12

The company has priced a $250 million public offering of American Depositary Shares at $21.50 per share, with underwriters holding an option for 1.74 million more shares.
The efficacy of Centessa Pharmaceuticals' NT2 dose is uncertain, with the company having only 5 patients on the highlighted dose, making it difficult to draw conclusions.
Morgan Stanley has maintained an Overweight rating on Centessa Pharmaceuticals, with a $27 target price, after the company's ORX750 outperformed Alkermes' drug.

Newcomers· Apr 1

New investors are interested in Centessa Pharmaceuticals' ($CNTA) recent 44% price surge, with some noting it's created a new 1-year high.
The $LLY / $CNTA merger announcement is sparking interest in the company, with some focusing on its potential to enter the sleep disorder market and its development of orexin-targeting drugs.
The high volume and RSI overbought signal on $CNTA's chart are causing some to take notice, with a few speculating on the company's potential for further growth.

Generated by AI

Centessa Pharmaceuticals

Centessa Pharmaceuticals plc American Depositary Receipt

Company Information

Location

Centessa Pharmaceuticals

Social

Apr 1

Sentiment

Mar 31

Topics

Analysts· Jun 22

Announcements· Mar 31

Community

Regulars· Nov 12

Newcomers· Apr 1

Also Discussed

Centessa Pharmaceuticals plc American Depositary Receipt

Company Information

Location

Social

Apr 1

Sentiment

Mar 31

Topics

Analysts· Jun 22

Announcements· Mar 31

Community

Regulars· Nov 12

Newcomers· Apr 1

Also Discussed